- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04214002
The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
A Prospective Study to Evaluate the Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Study Overview
Status
Detailed Description
The objective of this study is to analyze the selected wounds' natural history prior to including the selected wounds in the evaluation of safety and efficacy in Krystal Biotech's Phase III protocol of B-VEC.
Subjects will be enrolled upon obtaining consent and meeting eligibility criteria.
Patient Screening is done on-site, followed by the imaging of at least 1 wound, but up to 15 wounds. All remaining imaging will be performed remotely with a smartphone or tablet application.
Patients are on-trial for approximately four months.
Study Type
Contacts and Locations
Study Locations
-
-
California
-
Redwood City, California, United States, 94063
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written informed consent is provided. Patients 18 years of age and older, and parent(s)/legal guardian(s) of patients younger than 18 years of age, must provide written informed consent prior to participating in the study; additionally, informed assent will be obtained from patients younger than 18 years of age as specified by local requirements.
- Patient must have a documented diagnosis of DEB based on genetic analysis showing a mutation in COL7A1 or, in the opinion of the investigator, a confirmed diagnosis of DEB based on histologic criteria (antigen mapping or electron microscopy).
- Age: 6 months and older
- Patient must have at least 1 wound that is suitable for imaging, in the opinion of the investigator, at the time of enrollment.
- Patient is willing and able to undergo the protocol-specified procedures.
Exclusion Criteria:
- In the opinion of the investigator, inclusion poses an unacceptable risk to the patient or interpretation of these study data.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in wound surface area
Time Frame: Up to four months
|
Percent change in wound surface area from baseline will be measured from images uploaded to an imaging application.
|
Up to four months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Closure
Time Frame: Up to four months
|
The time it takes for a wound to completely close.
|
Up to four months
|
Duration of wound closure
Time Frame: Up to four months
|
If a closure occurs, the time a wound remains epithelialized after the first, and any subsequent closures.
|
Up to four months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KB-WM-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dystrophic Epidermolysis Bullosa
-
Krystal Biotech, Inc.CompletedDystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis BullosaUnited States
-
Krystal Biotech, Inc.CompletedDystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis BullosaUnited States
-
Krystal Biotech, Inc.RecruitingDystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis BullosaUnited States
-
Castle Creek Biosciences, LLC.TerminatedEpidermolysis Bullosa Dystrophica, RecessiveUnited States
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Universidad Carlos III Madrid (TERMeG); St John... and other collaboratorsUnknownEpidermolysis Bullosa Dystrophica, RecessiveSpain
-
Phoenicis TherapeuticsNot yet recruitingDystrophic Epidermolysis BullosaUnited States
-
Thomas Jefferson UniversityOnconova Therapeutics, Inc.RecruitingRecessive Dystrophic Epidermolysis BullosaUnited States
-
Castle Creek Biosciences, LLC.Active, not recruitingRecessive Dystrophic Epidermolysis BullosaUnited States
-
Phoenix Tissue Repair, Inc.Phoenix Tissue Repair, a BridgeBio companyCompletedRecessive Dystrophic Epidermolysis BullosaUnited States
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesCompletedRecessive Dystrophic Epidermolysis BullosaUnited States, Austria, France, Germany, United Kingdom